Evidence of ALL makes the screening of the peripheral blood superfluous for genetic alterations such as FIP1L1-PDGFRA gene fusion, reciprocal translocations involving 4q12 (PDGFRA), 5q31-q33 (PDGFRB), 8p11–12 (FGFR1), or 9p24 (JAK2) that are recommended by WHO [1] and are useful to decide risk and risk-adapted therapy for myeloid neoplasms. This evidence concerns the gene FGFR1 and myeloid neoplasm.